Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma

Proteasome inhibitor (PI) carfilzomib (CFZ) has activity superior to bortezomib (BTZ) and is increasingly incorporated in multiple myeloma (MM) frontline therapy and relapsed settings. Most MM patients ultimately experience PI-refractory disease, an unmet medical need with poorly understood biology...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia
Main Authors: Besse, A, Stolze, S C, Rasche, L, Weinhold, N, Morgan, G J, Kraus, M, Bader, J, Overkleeft, H S, Besse, L, Driessen, C
Format: Artigo
Language:Inglês
Published: Nature Publishing Group 2018
Subjects:
Original Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5808083/
https://ncbi.nlm.nih.gov/pubmed/28676669
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2017.212
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items